Campbell Wealth Management Takes $219,000 Position in Amgen Inc. (NASDAQ:AMGN)

Campbell Wealth Management acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 839 shares of the medical research company’s stock, valued at approximately $219,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. AMF Tjanstepension AB lifted its position in Amgen by 16.9% during the 3rd quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock worth $38,825,000 after acquiring an additional 17,387 shares in the last quarter. Creative Planning lifted its position in Amgen by 8.6% during the 3rd quarter. Creative Planning now owns 197,457 shares of the medical research company’s stock worth $63,402,000 after acquiring an additional 15,564 shares in the last quarter. Swedbank AB lifted its position in Amgen by 1.1% during the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock worth $173,639,000 after acquiring an additional 5,751 shares in the last quarter. Sumitomo Life Insurance Co. lifted its position in Amgen by 2.5% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 5,928 shares of the medical research company’s stock worth $1,910,000 after acquiring an additional 143 shares in the last quarter. Finally, Wolff Wiese Magana LLC raised its position in shares of Amgen by 7.5% in the 3rd quarter. Wolff Wiese Magana LLC now owns 9,641 shares of the medical research company’s stock valued at $3,106,000 after purchasing an additional 671 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Murdo Gordon sold 8,771 shares of the business’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total value of $2,585,603.09. Following the transaction, the executive vice president now owns 44,186 shares of the company’s stock, valued at $13,025,590.94. This trade represents a 16.56 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,405 shares of company stock worth $10,410,596. 0.69% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of recent analyst reports. Piper Sandler upped their target price on Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research report on Monday. Wells Fargo & Company cut their target price on Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a research report on Friday, January 10th. Redburn Partners cut their target price on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Piper Sandler Companies reaffirmed an “overweight” rating and issued a $310.00 target price on shares of Amgen in a research report on Thursday, January 2nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $314.09.

Amgen Price Performance

Shares of AMGN opened at $296.97 on Friday. The company has a market cap of $159.63 billion, a P/E ratio of 39.33, a PEG ratio of 3.01 and a beta of 0.56. The stock has a fifty day moving average price of $273.29 and a 200 day moving average price of $302.18. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.96. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, research analysts forecast that Amgen Inc. will post 20.59 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is 119.21%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.